Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry

Maria Manara, Roberto Caporali, Ennio G. Favalli, Vittorio Grosso, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Roberto Gorla, Chiara Bazzani, Enrico Fusaro, Raffaele Pellerito, Pier A. Rocchetta, Luigi Sinigaglia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. Methods We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. Results Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. Conclusion This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.

Original languageEnglish
Pages (from-to)804-809
Number of pages6
JournalClinical and Experimental Rheumatology
Volume35
Issue number5
Publication statusPublished - Jan 1 2017

Fingerprint

Psoriatic Arthritis
Ankylosing Spondylitis
Registries
Rheumatoid Arthritis
Survival
Therapeutics
golimumab
Proportional Hazards Models
Italy
Survival Rate

Keywords

  • Ankylosing spondylitis
  • Golimumab
  • Psoriatic arthritis
  • Retention rate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis : Data from the LORHEN registry. / Manara, Maria; Caporali, Roberto; Favalli, Ennio G.; Grosso, Vittorio; Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Gorla, Roberto; Bazzani, Chiara; Fusaro, Enrico; Pellerito, Raffaele; Rocchetta, Pier A.; Sinigaglia, Luigi.

In: Clinical and Experimental Rheumatology, Vol. 35, No. 5, 01.01.2017, p. 804-809.

Research output: Contribution to journalArticle

Manara, M, Caporali, R, Favalli, EG, Grosso, V, Atzeni, F, Sarzi-Puttini, P, Gorla, R, Bazzani, C, Fusaro, E, Pellerito, R, Rocchetta, PA & Sinigaglia, L 2017, 'Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry', Clinical and Experimental Rheumatology, vol. 35, no. 5, pp. 804-809.
Manara, Maria ; Caporali, Roberto ; Favalli, Ennio G. ; Grosso, Vittorio ; Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo ; Gorla, Roberto ; Bazzani, Chiara ; Fusaro, Enrico ; Pellerito, Raffaele ; Rocchetta, Pier A. ; Sinigaglia, Luigi. / Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis : Data from the LORHEN registry. In: Clinical and Experimental Rheumatology. 2017 ; Vol. 35, No. 5. pp. 804-809.
@article{b1d242009be34571a68ca894ba2dcc3b,
title = "Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry",
abstract = "Objective We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. Methods We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. Results Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3{\%}, 48{\%} for PsA, and 62.8{\%} for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. Conclusion This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.",
keywords = "Ankylosing spondylitis, Golimumab, Psoriatic arthritis, Retention rate, Rheumatoid arthritis",
author = "Maria Manara and Roberto Caporali and Favalli, {Ennio G.} and Vittorio Grosso and Fabiola Atzeni and Piercarlo Sarzi-Puttini and Roberto Gorla and Chiara Bazzani and Enrico Fusaro and Raffaele Pellerito and Rocchetta, {Pier A.} and Luigi Sinigaglia",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "35",
pages = "804--809",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

T2 - Data from the LORHEN registry

AU - Manara, Maria

AU - Caporali, Roberto

AU - Favalli, Ennio G.

AU - Grosso, Vittorio

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

AU - Gorla, Roberto

AU - Bazzani, Chiara

AU - Fusaro, Enrico

AU - Pellerito, Raffaele

AU - Rocchetta, Pier A.

AU - Sinigaglia, Luigi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. Methods We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. Results Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. Conclusion This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.

AB - Objective We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. Methods We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. Results Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. Conclusion This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.

KW - Ankylosing spondylitis

KW - Golimumab

KW - Psoriatic arthritis

KW - Retention rate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85029757853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029757853&partnerID=8YFLogxK

M3 - Article

C2 - 28770712

AN - SCOPUS:85029757853

VL - 35

SP - 804

EP - 809

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -